

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6852183

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	GW PHARMA LIMITED	03/29/2018
RECEIVING PARTY DATA		
Name:	GW RESEARCH LIMITED	
Street Address:	SOVEREIGN HOUSE VISION PARK, CHIVERS WAY, HISTON	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB24 9BZ	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17242075
CORRESPONDENCE DATA		
Fax Number:	(202)842-7899	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	zIPPatentDocketingMailboxUS@cooley.com,lpedersen@cooley.com,mwardrick@cool	
Correspondent Name:	COOLEY LLP ATTN: PATENT GROUP	
Address Line 1:	1299 PENNSYLVANIA AVE, NW	
Address Line 2:	SUITE 700	
Address Line 4:	WASHINGTON, D.C. 20004	
ATTORNEY DOCKET NUMBER:	GWPH-005/09US	
NAME OF SUBMITTER:	JONATHAN M. COUSIN	
SIGNATURE:	/Jonathan M. Cousin/	
DATE SIGNED:	08/06/2021	
Total Attachments: 60		
source=GWPH00509US Assignment#page1.tif		
source=GWPH00509US Assignment#page2.tif		
source=GWPH00509US Assignment#page3.tif		
source=GWPH00509US Assignment#page4.tif		
source=GWPH00509US Assignment#page5.tif		
source=GWPH00509US Assignment#page6.tif		

source=GWPH00509US Assignment#page7.tif
source=GWPH00509US Assignment#page8.tif
source=GWPH00509US Assignment#page9.tif
source=GWPH00509US Assignment#page10.tif
source=GWPH00509US Assignment#page11.tif
source=GWPH00509US Assignment#page12.tif
source=GWPH00509US Assignment#page13.tif
source=GWPH00509US Assignment#page14.tif
source=GWPH00509US Assignment#page15.tif
source=GWPH00509US Assignment#page16.tif
source=GWPH00509US Assignment#page17.tif
source=GWPH00509US Assignment#page18.tif
source=GWPH00509US Assignment#page19.tif
source=GWPH00509US Assignment#page20.tif
source=GWPH00509US Assignment#page21.tif
source=GWPH00509US Assignment#page22.tif
source=GWPH00509US Assignment#page23.tif
source=GWPH00509US Assignment#page24.tif
source=GWPH00509US Assignment#page25.tif
source=GWPH00509US Assignment#page26.tif
source=GWPH00509US Assignment#page27.tif
source=GWPH00509US Assignment#page28.tif
source=GWPH00509US Assignment#page29.tif
source=GWPH00509US Assignment#page30.tif
source=GWPH00509US Assignment#page31.tif
source=GWPH00509US Assignment#page32.tif
source=GWPH00509US Assignment#page33.tif
source=GWPH00509US Assignment#page34.tif
source=GWPH00509US Assignment#page35.tif
source=GWPH00509US Assignment#page36.tif
source=GWPH00509US Assignment#page37.tif
source=GWPH00509US Assignment#page38.tif
source=GWPH00509US Assignment#page39.tif
source=GWPH00509US Assignment#page40.tif
source=GWPH00509US Assignment#page41.tif
source=GWPH00509US Assignment#page42.tif
source=GWPH00509US Assignment#page43.tif
source=GWPH00509US Assignment#page44.tif
source=GWPH00509US Assignment#page45.tif
source=GWPH00509US Assignment#page46.tif
source=GWPH00509US Assignment#page47.tif
source=GWPH00509US Assignment#page48.tif
source=GWPH00509US Assignment#page49.tif
source=GWPH00509US Assignment#page50.tif
source=GWPH00509US Assignment#page51.tif
source=GWPH00509US Assignment#page52.tif
source=GWPH00509US Assignment#page53.tif
source=GWPH00509US Assignment#page54.tif

source=GWPH00509US Assignment#page55.tif
source=GWPH00509US Assignment#page56.tif
source=GWPH00509US Assignment#page57.tif
source=GWPH00509US Assignment#page58.tif
source=GWPH00509US Assignment#page59.tif
source=GWPH00509US Assignment#page60.tif

EXECUTION COPY

GW PHARMA LTD

- and -

GW RESEARCH LTD

ASSET PURCHASE BY WAY OF DEED

THIS DEED is dated 29 March 2018 and made

BETWEEN:

- (1) **GW PHARMA LIMITED**, incorporated in England and Wales with company number 03704998, whose registered address is Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK ("GWP"); and
- (2) **GW RESEARCH LIMITED**, incorporated in England and Wales with company number 03107561, whose registered address is Sovereign House, Vision Park, Histon, Cambridge CB24 9BZ, UK ("GWR").

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

- (E) The GWP Research Collaboration and Licence Agreement described in paragraph (C) has now expired and GWP wishes to sell and GWR wishes to purchase the GWP Pipeline Assets (as defined below) on the terms and conditions set out in this Agreement.

■ [REDACTED]

THE PARTIES AGREE THAT

■ [REDACTED]

■ [REDACTED]

[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1.1.15 "GWP Pipeline Patent Rights" means the Patent Rights filed by GWP under and pursuant to the terms of the GWP Research Collaboration and Licence Agreement, including those set out in Schedule 1.1.15 which includes published but not yet granted patent applications.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

1.1.21 "Patent Rights" means: (i) all national, regional and international patents and patent applications, including provisional patent applications; (ii) all patent applications filed

either from such patents, patent applications or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications; (iii) any and all patents that have issued or in the future issue from the foregoing patent applications (i) and (ii), including author certificates, inventor certificates, utility models, petty patents and design patents and certificates of invention; (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications (i), (ii) and (iii); and (v) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents.

[REDACTED]

[REDACTED]

[REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]

[REDACTED]

[REDACTED]

[illegible]

3. **CONSIDERATION**

3.1 **Purchase price**

The consideration for the sale and purchase of the GWP Pipeline Assets (including the agreement to assign the GW Pipeline Patent Rights and the GWP Pipeline Trademarks) shall be the amount of [REDACTED] ("Purchase Price"). The Purchase Price is payable in cash at Completion.

- [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
- [REDACTED]
- [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]

■ [REDACTED]
■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
■ [REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

■ [REDACTED]

■ [REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

§ 87(2)(b) [REDACTED]

(b) (7)(C), (b) (7)(D)

[REDACTED] [REDACTED]

§ 87(2)(b)

[illegible]

(b) (7)(C), (b) (7)(D)

[REDACTED]

[REDACTED]

(b) (7)(C), (b) (7)(D)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]


This Agreement has been executed as a deed and is delivered and takes effect on the date stated at the beginning of it.

14





SCHEDULE 1.15
GWP PATENT RIGHTS


15



17










21

22

23









26

Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	14/741,783	17/Jun/201	9,474,726	25/Oct/2016	Granted
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	US15/284,766	17/Jun/201			Pending
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	US15/449,084	04/Oct/201			Pending

Invention	Applicant	Country	Application No.	Applicatio n Date	Grant No.	Grant Date	Status
EPILEPSY							
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	US15/449,124	04/Oct/201 6			Pending
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	US15/449,185	04/Oct/201 6			Pending
USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GW Pharma Limited	USA	US15/449,204	04/Oct/201 6			Pending

30






Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status


USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	15/519,233	14/Oct/2015			Pending
---	-------------------	-----	------------	-------------	--	--	---------

Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status
USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	GW Pharma Limited	USA	15/519,244	14/Oct/2015			Pending

35



Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status
USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	14/881,954	13/Oct/2015			Pending




37

Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	14/881,969	13/Oct/2015			Pending
USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GW Pharma Limited	USA	US15/449,402	13/Oct/2015			Pending
USE OF CANNABINOIDS IN THE TREATMENT OF	GW Pharma Limited	USA	US15/449,535	13/Oct/2015			Pending

Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status
EPILEPSY							

40



41


Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status
[REDACTED]							
Absence Seizures	GW Pharma	USA	14/741,829	17/Jun/201			Pending

Invention	Applicant	Country			Application No.	Application Date	Grant No.	Grant Date	Status		
	Limited					5					


Invention	Applicant	Country	Application No.	Application Date	Grant No.	Grant Date	Status
[REDACTED]							
CBD A for use in epilepsy	GW Pharma Limited	USA	15/751,563	29/Jul/2016			Pending
[REDACTED]							

45

46





47





[REDACTED]


[REDACTED]























1. [REDACTED]

2. [REDACTED]

3. [REDACTED]

4. [REDACTED]

5. [REDACTED]

6. [REDACTED]


7. [REDACTED]

8. [REDACTED]

[REDACTED]


EXECUTED as a deed by GW
PHARMA LTD acting by
, a director, in the

presence of:


Name: LAURA A FOUGMAN
Occupation: EXECUTIVE ASST.
Address 21 CHURCHILL ROAD
LONDON NW2 5ED

EXECUTED as a deed by GW
RESEARCH LTD acting by

, a director, in the presence of:


Name: LAURA A FOUGMAN
Occupation: EXECUTIVE ASST.
Address 21 CHURCHILL ROAD
LONDON NW2 5ED


Director


Director